Literature DB >> 31902622

A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.

M Gohar Maqbool1, Constantine S Tam2, Ian M Morison3, David Simpson4, Peter Mollee5, Hans Schneider6, Henry Chan4, Surender Juneja7, Yasmin Harvey8, Lakshmi Nath9, Pravin Hissaria10, H Miles Prince11, Helen Wordsworth8, Stephen Opat12, Dipti Talaulikar13.   

Abstract

Waldenström macroglobulinaemia (WM) is an indolent non-Hodgkin lymphoma which usually presents with symptoms related to infiltration of bone marrow or other tissues like lymph nodes, liver or spleen and has certain unusual clinical manifestations, e.g., renal and central nervous system (CNS) involvement. It also has an array of laboratory features including hypersecretion of IgM, cryoglobulinaemia, increased plasma viscosity and identification of mutated MYD88L265P in more than 90% of cases. In this review, we aim to provide a guide to the laboratory investigations recommended for WM at initial diagnosis and at follow-up. A discussion on the nuances of diagnosis and differential diagnoses is followed by bone marrow (BM) assessment, measurement of paraprotein and other ancillary investigations. Recommendations are provided on laboratory work-up at diagnosis, in the asymptomatic follow-up phase, and during and post-treatment. Finally, we briefly discuss the implications of laboratory diagnosis in regard to recruitment and monitoring on clinical trials. Crown
Copyright © 2019. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CXCR4; IgM MGUS; IgM paraprotein; MYD88; Practical guide for Waldenström macroglobulinaemia; laboratory investigations for Waldenström macroglobulinaemia; lymphoplasmacytic lymphoma; transformed Waldenström macroglobulinaemia; work-up at diagnosis for Waldenström macroglobulinaemia; work-up for Waldenström macroglobulinaemia during and post treatment

Mesh:

Year:  2020        PMID: 31902622     DOI: 10.1016/j.pathol.2019.11.002

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  5 in total

Review 1.  Hyperviscosity syndromes; hemorheology for physicians and the use of microfluidic devices.

Authors:  Jamie O Musick; Kirby S Fibben; Wilbur A Lam
Journal:  Curr Opin Hematol       Date:  2022-07-18       Impact factor: 3.218

Review 2.  Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.

Authors:  Daniela Drandi; Philippe Decruyenaere; Martina Ferrante; Fritz Offner; Jo Vandesompele; Simone Ferrero
Journal:  Diagnostics (Basel)       Date:  2022-04-12

3.  Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry.

Authors: 
Journal:  BMC Med Res Methodol       Date:  2022-10-10       Impact factor: 4.612

4.  Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study.

Authors:  Xuejiao Yin; Lei Chen; Fengjuan Fan; Han Yan; Yuyang Zhang; Zhenli Huang; Chunyan Sun; Yu Hu
Journal:  Front Oncol       Date:  2020-09-10       Impact factor: 6.244

Review 5.  CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.

Authors:  John J Schmieg; Jeannie M Muir; Nadine S Aguilera; Aaron Auerbach
Journal:  Curr Oncol       Date:  2021-12-04       Impact factor: 3.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.